NVSNovartis PharmaceuticalsFinished
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Chronic Myelogenous Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 199 (final count)
- Started
- Oct 13, 2021
- Main results expected
- Mar 12, 2024
- Fully finished
- Feb 25, 2026
- Results posted
- Mar 27, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline
Measured over: Week 48
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04948333 · record last updated 2026-03-18 · checked 2026-11-09 15:47 UTC